St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical will accelerate its patent foramen ovale (PFO) R&D program for stroke treatment by acquiring Velocimed for more than $82.5 mil. under a definitive agreement, the firms said Feb. 15
You may also be interested in...
People In Brief
Former Lutonix chief Dennis Wahr takes helm at Innovative Pulmonary Solutions. FDA gets two new associate commissioners. More people news.
St. Jude Venture catheter
Firm gains 510(k) clearance for its Venture wire control catheter for use with a rapid exchange delivery platform. The rapid exchange delivery method accommodates shorter guidewires, which may result in quicker, easier coronary procedures, the firm says. The Venture catheter, first approved in 2005 for use with an over-the-wire system, features a deflectable tip, allowing interventional cardiologists to treat difficult-to-reach areas in the heart. St. Jude obtained Venture in its 2005 acquisition of Velocimed (1"The Gray Sheet" Feb. 21, 2005, p. 9)...
St. Jude Venture catheter
Firm gains 510(k) clearance for its Venture wire control catheter for use with a rapid exchange delivery platform. The rapid exchange delivery method accommodates shorter guidewires, which may result in quicker, easier coronary procedures, the firm says. The Venture catheter, first approved in 2005 for use with an over-the-wire system, features a deflectable tip, allowing interventional cardiologists to treat difficult-to-reach areas in the heart. St. Jude obtained Venture in its 2005 acquisition of Velocimed (1"The Gray Sheet" Feb. 21, 2005, p. 9)...